Mark A. Tomai

Overview

Best Publications

• Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

  Keith B. Gorden;Kevin S. Gorski;Sheila J. Gibson;Ross M. Kedl

  843
  Citations

• Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

  Sheila J Gibson;Jana M Lindh;Tony R Riter;Raymond M Gleason

  507
  Citations

• Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

  Unknown

  409
  Citations

• A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod

  Stephen K. Tyring;Istvan Arany;Margaret A. Stanley;Mark A. Tomai

  363
  Citations

• Cytokine induction by the immunomodulators imiquimod and S-27609.

  Traci L. Testerman;John F. Gerster;Linda M. Imbertson;Michael J. Reiter

  355
  Citations

• Development of a Topically Active Imiquimod Formulation

  John L. Chollet;Michael J. Jozwiakowski;Kenneth R. Phares;Michael J. Reiter

  339
  Citations

• The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

  John P Vasilakos;Mark A Tomai

  319
  Citations

• Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.

  Kevin O. Saunders;Esther Lee;Robert Parks;David R. Martinez

  259
  Citations

• Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.

  John P. Vasilakos;Rose M.A. Smith;Sheila J. Gibson;Jana M. Lindh

  250
  Citations

• Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.

  K Megyeri;W C Au;I Rosztoczy;N B Raj

  205
  Citations

• The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.

  Robert P. Burns;Barbara Ferbel;Mark Tomai;Richard Miller

  193
  Citations

• The antiviral activity of Toll-like receptor 7 and 7/8 agonists.

  Richard L Miller;Tze-Chiang Meng;Mark A Tomai

  186
  Citations

• Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists

  Kevin S. Gorski;Emily L. Waller;Jacqueline Bjornton-Severson;John A. Hanten

  186
  Citations

• Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

  Stefanie R. Mullins;John P. Vasilakos;Katharina Deschler;Iwen Grigsby

  182
  Citations

• The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.

  Mark A. Tomai;Linda M. Imbertson;Tamara L. Stanczak;Lorraine T. Tygrett

  180
  Citations

• Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules

  Mark A. Tomai;John P. Vasilakos;John C. Stolpa

  172
  Citations

• Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

  Kevin O. Saunders;Kevin Wiehe;Ming Tian;Priyamvada Acharya

  168
  Citations

• Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848.

  Cory L. Ahonen;Sheila J. Gibson;Rose M. Smith;Linda K. Pederson

  168
  Citations

• Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609

  Sheila J. Gibson;Linda M. Imbertson;Tamara L. Wagner;Traci L. Testerman

  167
  Citations

• Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5

  Istvan Arany;Stephen K Tyring;Margaret A Stanley;Mark A Tomai

  162
  Citations

• T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.

  Prabhu S. Arunachalam;Tysheena P. Charles;Vineet Joag;Venkata S. Bollimpelli

  153
  Citations

• Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells

  D E Spaner;Y Shi;D White;J Mena

  150
  Citations

• Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.

  David I. Bernstein;Christopher J. Harrison;Mark A. Tomai;Richard L Miller

  145
  Citations

• Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways

  Victoria J. Philbin;Victoria J. Philbin;David J. Dowling;David J. Dowling;Leighanne C. Gallington;Guadalupe Cortés;Guadalupe Cortés

  134
  Citations

• TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth

  David J. Dowling;David J. Dowling;Simon D. van Haren;Simon D. van Haren;Annette Scheid;Ilana Bergelson

  113
  Citations

• 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates

  Sudhir Pai Kasturi;Mohammed Ata Ur Rasheed;Mohammed Ata Ur Rasheed;Colin Havenar-Daughton;Mathew Pham

  112
  Citations

• Characterization of a Nontoxic Monophosphoryl Lipid A

  Arthur G Johnson;M. Tomai;L. Solem;L. Beck

  111
  Citations

• Methods and compositions for enhancing immune response

  Richard L. Miller;Mark A. Tomai;Ross M. Kedl;Isidro Angelo Eleazar Zarraga

  111
  Citations

• Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.

  Jeffrey A. Martinson;Alejandro Roman-Gonzalez;Allan R. Tenorio;Carlos J. Montoya

  110
  Citations

• A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

  Neal Van Hoeven;Christopher B Fox;Brian Granger;Tara Evers

  86
  Citations

• SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.

  Nanda Kishore Routhu;Narayanaiah Cheedarla;Venkata Satish Bollimpelli;Sailaja Gangadhara

  82
  Citations

• Immunostimulatory combinations and treatments

  Ross M Kedl;Mark A Tomai;John P Vasilakos

  80
  Citations

• New horizons in adjuvants for vaccine development.

  Steven G Reed;Mark Tomai;Michael J Gale

  49
  Citations